Abstracts tagged "Systemic lupus erythematosus (SLE)"

Abstract Number: 0056 • ACR Convergence 2022
Pilot Study to Implement the Type 1 & 2 SLE Model in an Academic Rheumatology Clinic
Amanda Eudy¹, Jennifer Rogers², Kai Sun³, Rebecca Sadun³, David Pisetsky⁴, Mithu Maheswaranathan², Jayanth Doss³, Lisa Criscione-Schreiber⁵ and Megan Clowse³, ¹Duke University, Raleigh, NC, ²Duke, Durham, NC, ³Duke University, Durham, NC, ⁴Duke University Medical Center, Durham, NC, ⁵Duke University School of Medicine, Durham, NC
Background/Purpose: The Type 1 & 2 SLE Model was developed to better explain the signs, symptoms, and management goals of SLE to patients. We assembled…
Abstract Number: 0110 • ACR Convergence 2022
Does Access Reduce Excess Use? Lupus Outcomes in Two Distinct Socioeconomic Groups Seen by University Rheumatologists
Alissa Chandler¹, Rodney Tehrani¹ and Varun Bhalla², ¹Loyola University Medical Center, Maywood, IL, ²Loyola University Medical cneter, Chicago, IL
Background/Purpose: SLE is a multi-organ chronic autoimmune disease, which requires chronic medication use and close follow up with a rheumatologist. Poor disease control can lead…
Abstract Number: 0326 • ACR Convergence 2022
Mapping Anti-Mitochondrial Antibodies over Time in a Lupus Inception Cohort
Yann Becker¹, Éric Boilard¹, Emmanuelle Rollet-Labelle¹, Christian Lood², Anne-Sophie Julien³, Joannie Leclerc¹, Tania Lévesque¹, Murray Urowitz⁴, John Hanly⁵, Caroline Gordon⁶, Sang-Cheol Bae⁷, Juanita Romero-Diaz⁸, Jorge Sanchez-Guerrero⁹, Ann E Clarke¹⁰, Sasha Bernatsky¹¹, Daniel Wallace¹², David Isenberg¹³, Anisur Rahman¹⁴, Joan Merrill¹⁵, Dafna Gladman¹⁶, Ian N. Bruce¹⁷, Michelle Petri¹⁸, Ellen M. Ginzler¹⁹, Mary Anne Dooley²⁰, Rosalind Ramsey-Goldman²¹, Susan Manzi²², Andreas Jönsen²³, Graciela Alarcón²⁴, Ronald van Vollenhoven²⁵, Cynthia Aranow²⁶, Guillermo Ruiz-Irastorza²⁷, S. Sam Lim²⁸, Murat Inanc²⁹, Kenneth Kalunian³⁰, Soren Jacobsen³¹, Christine Peschken³², Diane Kamen³³, Anca Askanase³⁴, Jill Buyon³⁵ and Paul R Fortin³⁶, ¹Centre de Recherche ARThrite, CHU de Québec - Université Laval, Québec, QC, Canada, ²Division of Rheumatology, University of Washington, Seattle, WA, ³Université Laval, Québec, QC, Canada, ⁴University of Toronto, University Health Network, Schroeder Arthritis Institute, Toronto, ON, Canada, ⁵Division of Rheumatology, Queen Elizabeth II Health Sciences Center (Nova Scotia Rehabilitation Site) and Dalhousie University, Halifax, NS, Canada, ⁶Rheumatology Research Group, Institute of Inflammation and Ageing, College of Medical and Dental Sciences, University of Birmingham, Birmingham, United Kingdom, ⁷Hanyang University Medical Center, Seoul, Republic of Korea, ⁸Instituto Nacional de Ciencias Medicas y Nutricion SZ, Ciudad de México, Mexico, ⁹Mount Sinai Hospital and University Health Network, University of Toronto, Toronto, ON, Canada, ¹⁰University of Calgary, Division of Rheumatology, Cumming School of Medicine, Calgary, AB, Canada, ¹¹Research Institute of the McGill University Health Centre, Montréal, QC, Canada, ¹²Cedars-Sinai Medical Center, Los Angeles, CA, ¹³University College London, London, United Kingdom, ¹⁴Centre for Rheumatology, Department of Medicine, University College London, London, United Kingdom, ¹⁵Oklahoma Medical Research Foundation, Oklahoma City, OK, ¹⁶Toronto Western Hospital, Schroeder Arthritis Institute, Toronto, ON, Canada, ¹⁷Centre for Epidemiology Versus Arthritis, Faculty of Biology, Medicine and Health, The University of Manchester, Manchester, United Kingdom, ¹⁸Johns Hopkins University School of Medicine, Division of Rheumatology, Baltimore, MD, ¹⁹SUNY Downstate Health Sciences University, Department of Medicine, Brooklyn, NY, ²⁰Raleigh Neurology Associates, Chapel Hill, NC, ²¹Northwestern University Feinberg School of Medicine, Chicago, USA, Chicago, IL, ²²Allegheny Health Network, Lupus Center of Excellence, Wexford, PA, ²³Department of Clinical Sciences, Lund, Section for Rheumatology, Lund University, Lund and Skåne University Hospital, Lund, Sweden, ²⁴The University of Alabama at Birmingham, Oakland, ²⁵Amsterdam University Medical Centers, Amsterdam, Netherlands, ²⁶Feinstein Institutes for Medical Research, Manhasset, NY, ²⁷Autoimmune Diseases Research Unit, Biocruces Bizkaia Health Research Institute, Hospital Universitario Cruces, UPV/EHU, Barakaldo, Spain, ²⁸Emory University, Atlanta, GA, ²⁹Division of Rheumatology, Department of Internal Medicine, Istanbul Medical Faculty, Istanbul University, Istambul, Turkey, ³⁰University of California San Diego, La Jolla, CA, ³¹Rigshospitalet, Copenhagen, Denmark, ³²University of Manitoba, Winnipeg, MB, Canada, ³³Medical University of South Carolina, Charleston, SC, ³⁴Columbia University Medical Center, New York, NY, ³⁵NYU Grossman School of Medicine, New York, NY, ³⁶Centre ARThrite - CHU de Québec - Université Laval, Québec, QC, Canada
Background/Purpose: Mitochondria can be both pro-inflammatory and antigenic. We hypothesize (1) that anti-mitochondrial antibodies (AMA) are present in lupus and (2) can predict outcomes. Our…
Abstract Number: 0344 • ACR Convergence 2022
Therapeutic Thresholds of Hydroxychloroquine Blood Levels: Physiologic and Social Determinants of Low Hydroxychloroquine Blood Levels
Shivani Garg¹, Betty Chewning², Brad Astor³ and Christie Bartels⁴, ¹University of Madison, School of Medicine and Public Health, Madison, WI, ²University of Wisconsin, School of Pharmacy, Madison, WI, ³University of Wisconsin, School of Medicine and Public Health, Madison, WI, ⁴University of Wisconsin School of Medicine and Public Health, Madison, WI
Background/Purpose: Lupus, the leading cause of chronic kidney disease (CKD) in young women, is treated with Hydroxychloroquine (HCQ) which is primarily excreted by kidneys. Yet…
Abstract Number: 0366 • ACR Convergence 2022
Phase II Trial of Enpatoran in Patients Hospitalized with COVID-19 Pneumonia
John McKinnon¹, Joel Santiaguel², Claudia Murta De Oliveira³, Dongzi Yu⁴, Mukhy Khursheed⁵, Flavie Moreau⁶, Lena Klopp-Schulze⁷, Jamie Shaw⁸, Sanjeev Roy⁹ and Amy Kao¹⁰, ¹Department of Medicine, Henry Ford Hospital, Detroit, MI, ²Internal Medicine, Quirino Memorial Medical Center, Quezon City, Philippines, ³Ambulatório de Pesquisa Clínica, Santa Casa de Misericórdia, Belo Horizonte, Brazil, ⁴Global Clinical Development, EMD Serono, Billerica, MA, ⁵Global Patient Safety, Merck Serono Ltd., an affiliate of Merck KGaA, Darmstadt, Germany, ⁶Global Biostatistics, EMD Serono, Billerica, MA, ⁷Translational Medicine, the healthcare business of Merck KGaA, Darmstadt, Germany, ⁸Translational Medicine, EMD Serono, Billerica, MA, ⁹Global Clinical Development, Ares Trading SA, an affiliate of Merck KGaA, Darmstadt, Germany, ¹⁰EMD Serono, Billerica, MA
Background/Purpose: Enpatoran is a selective and potent dual toll-like receptor (TLR) 7/8 inhibitor in development for the treatment of cutaneous and systemic lupus erythematosus (CLE/SLE).…
Abstract Number: 0631 • ACR Convergence 2022
Perfluoroalkyl Substances and Community Vulnerability: Associations with Lupus-Related Autoantibodies and Disease
Emily Vara, Dulaney Wilson, John Pearce, Jim Oates and Diane Kamen, Medical University of South Carolina, Charleston, SC
Background/Purpose: Perfluoroalkyl substances (PFAS) are a class of persistent organic pollutants found in nonstick products, water repellant fabrics, fire-retardant foams, and food packaging. Highly stable,…
Abstract Number: 0649 • ACR Convergence 2022
Phosphofructokinase P Fine-Tunes T Regulatory Cell Metabolism, Function and Stability in Systemic Autoimmunity
Marc Scherlinger¹, Wenliang Pan², Ryo Hisada¹, Milena Vukelic³, Masataka Umeda¹, Afroditi Boulougoura², Maria Tsokos¹ and George Tsokos², ¹BIDMC Harvard University, Boston, MA, ²Division of Rheumatology and Clinical Immunology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, ³Albert Einstein College of Medicine, New York, NY
Background/Purpose: Systemic lupus erythematosus (SLE) is characterized by a defective T regulatory (Treg) cell compartment which participate in immune dysregulation. Although the underlying mechanism are…
Abstract Number: 0669 • ACR Convergence 2022
Understanding How Type I Interferon Modulates Langerhans Cell ADAM17 to Promote Photosensitivity in Lupus
Thomas Li¹, Ethan Seltzer¹, Victoria Zyulina¹, Keila Veiga², Noa Schwartz³, Yurii Chinenov¹, David Oliver¹, Jose Lora⁴, Ali Jabbari⁵, Yong Liu¹, Hafsa Munir¹, William Shipman¹, Marvin Sandoval¹, Isabel Sollohub¹, william ambler¹, Bikash Mishra⁴, sarah taber¹, karen onel¹, Mehdi Rashighi⁶, james krueger⁷, Niroshana Anandasabapathy⁴, Carl Blobel¹ and theresa Lu¹, ¹Hospital for Special Surgery, New York, NY, ²Maria Fareri Children's Hospital, New York, NY, ³Albert Einstein College of Medicine, New York, NY, ⁴Weill Cornell Medicine, New York, NY, ⁵University of Iowa, Iowa City, IA, ⁶University of Massachusetts Medical School, Worcester, MA, ⁷Rockefeller University, New York, NY
Background/Purpose: Photosensitivity is a hallmark symptom of lupus erythematosus (LE), in which patients develop inflammatory skin lesions in response to ultraviolet radiation (UVR). In examining…
Abstract Number: 0949 • ACR Convergence 2022
Systemic Lupus Erythematosus Women with Lupus Nephritis in Pregnancy Therapeutic CHallenge (SWITCH): The Systemic Lupus International Collaborating Clinics Experience
Joo Young (Esther) Lee¹, Arielle Mendel², Anca Askanase³, Sang-Cheol Bae⁴, Jill Buyon⁵, Ann E Clarke⁶, Nathalie Costedoat-Chalumeau⁷, Paul R Fortin⁸, Dafna Gladman⁹, John Hanly¹⁰, Murat Inanc¹¹, David Isenberg¹², Anselm Mak¹³, Marta Mosca¹⁴, Michelle Petri¹⁵, Anisur Rahman¹⁶, Rosalind Ramsey-Goldman¹⁷, Jorge Sanchez-Guerrero¹⁸, Murray Urowitz¹⁹, Daniel Wallace²⁰, Sasha Bernatsky²¹ and Evelyne Vinet², ¹McGill University, Montréal, QC, Canada, ²McGill University Health Centre, Montréal, QC, Canada, ³Columbia University Medical Center, New York, NY, ⁴Hanyang University Medical Center, Seoul, Republic of Korea, ⁵NYU Grossman School of Medicine, New York, NY, ⁶University of Calgary, Division of Rheumatology, Cumming School of Medicine, Calgary, AB, Canada, ⁷Inserm DR Paris 5, Paris, France, ⁸Centre ARThrite - CHU de Québec - Université Laval, Québec, QC, Canada, ⁹Toronto Western Hospital, Schroeder Arthritis Institute, Toronto, ON, Canada, ¹⁰Division of Rheumatology, Queen Elizabeth II Health Sciences Center (Nova Scotia Rehabilitation Site) and Dalhousie University, Halifax, NS, Canada, ¹¹Division of Rheumatology, Department of Internal Medicine, Istanbul Medical Faculty, Istanbul University, Istambul, Turkey, ¹²University College London, London, United Kingdom, ¹³Division of Rheumatology, Department of Medicine, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore, ¹⁴Rheumatology Unit, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy, ¹⁵Johns Hopkins University School of Medicine, Division of Rheumatology, Baltimore, MD, ¹⁶Centre for Rheumatology, Department of Medicine, University College London, London, United Kingdom, ¹⁷Northwestern University Feinberg School of Medicine, Chicago, USA, Chicago, IL, ¹⁸Sinai Health System, Toronto, ON, Canada, ¹⁹University of Toronto, University Health Network, Schroeder Arthritis Institute, Toronto, ON, Canada, ²⁰Cedars-Sinai Medical Center, Los Angeles, CA, ²¹Research Institute of the McGill University Health Centre, Montréal, QC, Canada
Background/Purpose: One-third of women with SLE develop lupus nephritis (LN), and most receive mycophenolate mofetil (MMF). However, MMF is teratogenic, and needs to be switched…
Abstract Number: 0976 • ACR Convergence 2022
Low-dose Belimumab and Antimalarial Agents Prevent Renal Flares in Systemic Lupus Erythematosus: Results from Four Randomised Clinical Trials
Alvaro Gomez¹, Sandra Jägerback¹, Christopher Sjöwall² and Ioannis Parodis³, ¹Division of Rheumatology, Department of Medicine, Solna, Karolinska Institutet, Stockholm, Sweden, ²Department of Biomedical and Clinical Sciences, Division of Inflammation and Infection, Linköping University, Linköping, Sweden, ³Karolinska Institutet, Stockholm, Sweden
Background/Purpose: Renal flares contribute substantially to morbidity, renal survival and death in systemic lupus erythematosus (SLE). Identification of pharmacological strategies for the prevention of renal…
Abstract Number: 0993 • ACR Convergence 2022
SARS-CoV-2 Vaccine Side Effects and Infections in SLE
Laura Yan¹, Arielle Mendel², Evelyne Vinet², Fares Kalache³, Jennifer Lee¹, Popi Panaritis² and Sasha Bernatsky¹, ¹Research Institute of the McGill University Health Centre, Montréal, QC, Canada, ²McGill University Health Centre, Montréal, QC, Canada, ³McGill University Health Center, Montréal, QC, Canada
Background/Purpose: SLE patients are an especially vulnerable population in the face of the COVID pandemic due to their dysregulated endogenous immune system, further downregulated by…
Abstract Number: 1118 • ACR Convergence 2022
Monocyte Transcriptomic Analysis Uncovers Heterogeneous Gene Expression Profiles in Systemic Lupus Erythematous (SLE) with and Without Subclinical Atherosclerosis
Laurel Woodridge¹, Elvira Chocano Navarro², George Robinson¹, Paul Ashford¹, Kirsty Waddington³, Anisur Rahman⁴, Christine Orengo⁵, Ines Pineda-Torra⁶ and Elizabeth Jury¹, ¹University College London, London, United Kingdom, ²VIHR, Barcelona, Spain, ³University College London (alumni), London, United Kingdom, ⁴Centre for Rheumatology, Department of Medicine, University College London, London, United Kingdom, ⁵ISMB / UCL, London, United Kingdom, ⁶Cabimer, Sevilla, Spain
Background/Purpose: A leading cause of mortality in SLE is cardiovascular disease (CVD) through accelerated atherosclerosis: the build-up of cells and lipids in the vascular wall.…
Abstract Number: 1297 • ACR Convergence 2022
A Paediatric-Adult Provider Dyad Care Model Improves Transition from Paediatric to Adult Health Care for Youth with Childhood-Onset Systemic Lupus Erythematosus
Tala El Tal¹, Abdulaziz el Mutairi¹, Amanda Steiman² and Earl Silverman³, ¹The Hospital for Sick Children, Division of Rheumatology, Department of Paediatrics, University of Toronto, Toronto, ON, Canada, ²Sinai Health System, Toronto, ON, Canada, ³The Hospital for Sick Children and University of Toronto, Toronto, ON, Canada
Background/Purpose: Systemic lupus erythematosus (SLE) is a chronic multi-system autoimmune disease affecting 1 in 1000 individuals, of whom 20% develop the disease in childhood. Childhood-onset…
Abstract Number: 1381 • ACR Convergence 2022
Health Related Quality of Life in Children with Systemic Lupus Erythematosus
Julie Samuels¹, Rula Issa², Lauren Robinson³ and Rebecca Trachtman¹, ¹Icahn School of Medicine at Mount Sinai, New York, NY, ²Phillips School of Nursing at Mount Sinai, New York, NY, ³Hospital for Special Surgery/New York Presbyterian-Weill Cornell, New York, NY
Background/Purpose: The importance of patient-reported outcomes and health-related quality of life (HRQOL) is increasingly recognized in healthcare. Adults with Systemic Lupus Erythematosus (SLE) have poor…
Abstract Number: 1454 • ACR Convergence 2022
A High Genetic Risk of SLE Is Associated with an Increased Risk of Myocardial Infarction; A Combined Observational and Mendelian Randomization Study
Sarah Reid¹, Johanna K Sandling¹, Pascal Pucholt¹, Ahmed Sayadi¹, Christopher Sjöwall², Karoline Lerang³, Andreas Jönsen⁴, Anders A Bengtsson⁴, Øyvind Molberg³, Anna Rudin⁵, Solbritt Rantapää-Dahlqvist⁶, Lars Ronnblom⁷ and Dag Leonard¹, ¹Rheumatology and Science for Life Laboratory, Department of Medical Sciences, Uppsala University, Uppsala, Sweden, ²Department of Biomedical and Clinical Sciences, Division of Inflammation and Infection, Linköping University, Linköping, Sweden, ³Department of Rheumatology, Oslo University Hospital, Oslo, Norway, Oslo, Norway, ⁴Department of Clinical Sciences, Lund, Section for Rheumatology, Lund University, Lund and Skåne University Hospital, Lund, Sweden, ⁵Department of Rheumatology and Inflammation Research, Institute of Medicine, Sahlgrenska Academy of University of Gothenburg, Gothenburg, Sweden, ⁶Department of Public Health and Clinical Medicine, Rheumatology, Umeå University, Umeå, Sweden, ⁷Uppsala University, Uppsala, Sweden
Background/Purpose: The reasons for the high cardiovascular morbidity in patients with SLE are not fully understood. Here, we combine a mendelian randomization (MR) approach and…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].